Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole for RLS in Opioid Withdrawal
NCT04759703Phase 3Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pramipexole in restless legs syndrome (RLS), sponsored by Massachusetts General Hospital. Started Jan 2022; status: terminated.
02
Drugs
pramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT04759703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759703.